GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Palash Securities Ltd

Palash Securities: Suraj Kumar Agrawal appointed Managing Director for 3 years

MANAGEMENT ● No Immediate Change MEDIUM RISK
📅 Filed on BSE: 30 Mar 2026, 04:51 PM IST  ·  BSE ID: 8ab0569c-3f19-4b34-ba24-568dc838103b
View Original BSE Filing (PDF)
💡
In Simple Terms
Palash Securities has appointed a new Managing Director to replace the outgoing one whose 3-year term just ended.
🤖 AI Summary
  • Suraj Kumar Agrawal (DIN: 03260442) appointed Managing Director for 3 years from 30 March 2026
  • Replaces Chand Bihari Patodia whose MD tenure expired 29 March 2026 after three years
  • Appointment effective immediately, without remuneration, subject to shareholder approval
  • Agrawal added to reconstituted Audit Committee as member alongside three independent directors
  • Board authorized Agrawal, CFO Sharma, and Company Secretary Mishra to jointly determine disclosure materiality
🔢 Key Numbers — exact figures from BSE filing, not rounded
MD appointment tenure
3 years from 30 March 2026 to 29 March 2029
MD remuneration
Without any remuneration
Previous MD tenure end
29 March 2026
🏢 How This Affects the Company
⚙️
Operational Impact
Leadership transition completed without governance gap. New MD assumes responsibility for daily operations, strategic decisions, and Key Managerial Personnel duties from 30 March 2026. Audit Committee reconstituted to include new MD.
👥 What This Means For Shareholders
✅
Action Required
Shareholders must approve Agrawal's MD appointment at forthcoming general meeting; voting eligibility depends on shareholding date.
👤
Who Is Affected
All equity shareholders must vote on MD appointment approval. No differentiation by shareholding size or class mentioned in filing.
🔍
Management Signal
Board selected internal or known candidate (DIN: 03260442) for continuity; unpaid role suggests founder/promoter-aligned decision or cost discipline.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Shareholder approval vote on Agrawal's MD appointment — check passing resolution at AGM/EGM within 30 days
Audit Committee meeting minutes — verify Agrawal's participation and contribution from 30 March 2026 onwards
MD remuneration details clarification — watch for any supplementary disclosure on unpaid status or future terms
MEDIUM RISK MD appointment pending shareholder approval; unpaid role clarity needed; 3-year fixed tenure creates succession planning visibility for 2029.
💡 Investor Takeaway
Board approved 3-year MD appointment of Suraj Kumar Agrawal from 30 March 2026, effective immediately after predecessor's term expired 29 March 2026. Appointment subject to shareholder approval; no remuneration specified. Audit Committee reconstituted with new MD as member.
⚖️ Strengths & Concerns

✅ Positives

  • Seamless MD succession — outgoing tenure ended 29 March, replacement effective 30 March, no operational gap
  • New MD not debarred by SEBI or any authority per Board confirmation, meets regulatory standards

⚠️ Concerns

  • New MD appointed without remuneration — unclear if temporary unpaid arrangement or permanent no-pay role
  • Appointment subject to shareholder approval — not yet formally confirmed by voting; pending EGM or AGM
📅 Company Track Record
Chand Bihari Patodia served as MD for 3 years (30 March 2023 – 29 March 2026) per prior filing dated 29 March 2026. Agrawal assumes role on 30 March 2026 with no stated gap. Palash Securities incorporated 2015; BSE listing status active (Symbol: PALASHSECU, Code: 540648).

Based on publicly available historical data. For context only.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.